Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 5, 2022

Gritstone reports positive data from initial arm of Covid-19 vaccine trial

In the trial, the vaccine was well-tolerated with favourable safety profile.

By Vishnu Priyan

Gritstone bio has reported positive results from the first cohort of Phase I CORAL-BOOST clinical trial of its CORAL self-amplifying mRNA (samRNA) vaccine for Covid-19.

Findings showed that the 10µg vaccine dose offered robust neutralising antibody responses to Spike and strong CD8+ T cell responses.

One of four trials of the CORAL programme, CORAL-BOOST is assessing the reactogenicity, safety and immunogenicity of the vaccine directed against Spike and highly conserved non-Spike T cell epitopes (TCE) as a Covid-19 booster shot.

This ongoing trial in the UK enrolled healthy adult subjects aged 60 years or above and were vaccinated with two doses of AstraZeneca’s AZD1222 (Vaxzevria) Covid-19 vaccine.

New CD8+ T cell responses across a wide range of non-spike epitopes, including several established T cell targets, were observed in the trial, which indicates the vaccine’s variant-proof immunity potential.

The vaccine was also found to be well-tolerated in the trial.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

It also showed an encouraging safety profile without any grade 3/4 side effects or unexpected reactogenicity or safety issues noted in ten healthy trial adult subjects.

Gritstone bio co-founder, president and CEO Andrew Allen said: “We designed our Covid-19 vaccines to drive broad CD8+ T cell immunity, an additional key layer of protection against viruses.

“This innovation enables the inclusion of a wide array of highly conserved viral epitopes, potentially creating an immune state that may offer more robust clinical protection against current and future SARS-CoV-2 variants and be a first step toward developing a pan-coronavirus vaccine.”

Presently, the trial dose-escalated to a 30mg dose of the vaccine.

With the latest development, the company is modifying the trial to raise the subject enrolment to 120 and assess the inclusion of a second samRNA-Spike-TCE dose of the shot.

Last September, Gritstone dosed the first subjects in a Phase I trial of a self-amplifying mRNA Covid-19 vaccine.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU